Pfizer Inc. $PFE Shares Acquired by Sunpointe LLC

Key Points

• Sunpointe LLC significantly increased its stake in Pfizer by 485.7% in the second quarter, acquiring a total of 54,164 shares valued at approximately $1.3 million.
• Major hedge funds have also modified their holdings of Pfizer, with institutional investors now owning 68.36% of the company's stock.
• Pfizer recently reported earnings of $0.78 EPS for the last quarter, exceeding analysts' expectations, and has declared a quarterly dividend yielding 7.2%.

Sunpointe LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 485.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,164 shares of the biopharmaceutical company's stock after acquiring an additional 44,916 shares during the quarter. Sunpointe LLC's holdings in Pfizer were worth $1,313,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Pacer Advisors Inc. increased its stake in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Amundi grew its holdings in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Nuveen LLC purchased a new position in shares of Pfizer during the 1st quarter worth $389,861,000. Goldman Sachs Group Inc. grew its holdings in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America increased their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group increased their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

Shares of NYSE PFE opened at $23.88 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The firm has a market capitalization of $135.77 billion, a PE ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The stock's 50-day simple moving average is $24.73 and its 200-day simple moving average is $24.25.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.